

Technology Advisory Committee A Interests Register

Topic: Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of early and locally advanced non-metastatic triple-negative breast cancer [ID1500]

Publication Date: 14/12/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Radha Todd	TA Committee Member	Direct-financial	Dr Todd has been a member of a Pfizer advisory board between September and November 2021.		25/08/22		It was agreed that this declaration would not prevent them from participating in this discussion.